Status and phase
Conditions
Treatments
About
Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a vasoconstrictor that may restore proper circulation and kidney function in patients with HRS.
Full description
Vasoconstrictors are considered a promising approach to treat HRS due to the significant vasodilation of the splanchnic circulation that contributes to systemic arterial underfilling and leads to functional decline of the kidney in these patients. Vasoconstrictors currently in use are associated with reduced organ perfusion and have marginal effect on sodium excretion. The vasoconstrictor angiotensin II has been shown to produce significant sodium excretion and urine output in patients with cirrhosis and ascites, supporting its potential utility in the treatment of HRS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with HRS, as defined by the International Ascites Club [1]:
Or patients with HRS due to acute alcoholic hepatitis
Patient is able to undergo a reliable neurologic exam, as determined by the investigator
Patient or legal surrogate is willing and able to provide written informed consent
Patient is willing and able to comply with all protocol requirements
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
6 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal